Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes ...

Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on ...

Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PI ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has enrolled ...

President John Dramani Mahama has inaugurated a Committee to oversee the transfer of the University of Ghana Medical Centre ...

The CEO of GH Research, Dr. Velichka Valcheva, pointed out that the response addressed the FDA’s requests with comprehensive ...

Rahway, New Jersey Wednesday, July 9, 2025, 13:00 Hrs [IST] ...

Fintel reports that on July 8, 2025, Ladenburg Thalmann initiated coverage of Cardiff Oncology (NasdaqCM:CRDF) with a Buy recommendation. Analyst Price Forecast Suggests 272.32% Upside As of June 20, ...

According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited ( ICLR 1.86 ...

Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over ...

The hunt for a medical breakthrough has been caught up in the Trump administration's political assault on the university.

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...